Ziihera (zanidatamab-hrii)

Product

Last mentioned: Mar 18, 2026

Timeline

  1. Anticipated Regulatory Milestones

    Potential for further regulatory filings based on ongoing Phase 3 data.

  2. AACR Annual Meeting

    Expected dates for the 2026 AACR meeting where Ziihera data will be showcased.

  3. Presentation Announcement

    Zymeworks announces multiple abstracts accepted for AACR 2026.

Stories mentioning Ziihera (zanidatamab-hrii) 1

clinical-trial Bullish

Zymeworks to Present Key Ziihera Clinical Data at 2026 AACR Annual Meeting

Zymeworks Inc. (ZYME) has announced multiple upcoming presentations for its lead asset, Ziihera (zanidatamab-hrii), at the 2026 AACR Annual Meeting. These presentations are expected to showcase the therapeutic's efficacy and safety across various HER2-expressing cancers, reinforcing its position in the competitive oncology landscape.

2 sources